Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$5.31
-$0.03(-0.56%)
At close: 4:00 PM EDT
$5.31
-$0.03(-0.56%)
Day’s Range― - ―
52-Week Range$2.75 - $12.15
Previous CloseN/A
Volume984.13K
Average Volume (3M)6.63M
Market Cap
$3.67B
Enterprise Value$1.97K
Total Cash (Recent Filing)$540.10M
Total Debt (Recent Filing)$135.62M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding324,047,360
10 Day Avg. Volume4,701,846
30 Day Avg. Volume6,632,648
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.17Price Target Upside223.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$25.25M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity RunwaySubstantial cash, government funding and at least three years of planned pipeline support reduce near-term financing risk. This gives AbCellera flexibility to fund clinical programs and platform investment while pursuing partnerships.
Strategic Partnership TractionPartnerships validate AbCellera’s T-cell engager capabilities and provide non-dilutive funding, external development support and potential royalties. They also broaden commercial reach and create multiple opportunities for downstream economics.
Integrated Antibody PlatformAn integrated platform can improve control over antibody discovery and early development, supporting repeat collaborations and faster candidate progression. Its breadth may strengthen AbCellera’s role across more stages of the biologics value chain.
Bears Say
Declining Revenue And Deep LossesFalling revenue alongside very large operating losses shows that the current cost base is not supported by recurring business activity. Sustained losses could weaken capital efficiency and increase dependence on financing, milestones or successful pipeline outcomes.
Negative Cash GenerationPersistent cash outflows indicate that operations and internal development currently consume capital rather than generate it. Although liquidity is strong, continued burn could reduce financial flexibility over time if partnerships or clinical programs do not deliver.
Clinical Execution And Revenue Concentration RiskPipeline value depends on uncertain clinical efficacy and timely execution, while limited recurring or product revenue leaves results reliant on collaborations and milestones. Failed studies or delays could therefore affect both funding visibility and long-term growth.
AbCellera Biologics News
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $2.75 and its highest was $12.15 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $3.67B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.016.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.17.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 324,047,360 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went up 10.304%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.17 (223.29% Upside)
$17.17 (223.29% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 82%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.74%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$17.17
▲(223.29% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
38.59% Insiders
4.40% Mutual Funds
18.51% Other Institutional Investors
36.86% Public Companies and Individual Investors